Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Akcea Therapeutics

Akcea Therapeutics
2015 FOUNDED
PUBLIC STATUS
201-300 EMPLOYEES
AKCA STOCK SYMBOL
$17.64 SHARE PRICE (As of Friday Closing)
Description

Akcea Therapeutics Inc is a late stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. Its most advanced drug, volanesorsen, has completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.

Website
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 55 Cambridge Parkway
  • Cambridge, MA 02142
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Akcea Therapeutics’s full profile, request a free trial.

Akcea Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$13.90 - $35.82 $1.66B $17.61 -$1.26 290K 93.9M

Akcea Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 1,151,069 2,369,966 869,032
Revenue 221,261 64,867 43,401 0
EBITDA (103,673) (222,197) (118,325) (83,086)
Net Income (112,191) (225,821) (121,559) (83,217)
Total Assets 383,167 365,261 268,804 10,684
Total Debt 14,558 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Akcea Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Akcea Therapeutics‘s full profile, request access.

Request full access to PitchBook

Akcea Therapeutics Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CymaBay Therapeutics Formerly PE-Backed Newark, CA 00 00000 00000000 00000
000 00000000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
000000 000000 Formerly VC-backed Marseille, France 000 00000 00000000000 00000
0000000000 Venture Capital-Backed Abingdon, United Kingdom 000 00000 00000000000 00000
000000 00000000000 Venture Capital-Backed San Diego, CA 00 000.00 00000000000 000.00
To view this company’s complete list of competitors, request access »

Akcea Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Akcea Therapeutics‘s full profile, request access.

Request full access to PitchBook

Akcea Therapeutics Executive Team (7)

Name Title Board
Seat
Contact
Info
Michael MacLean Chief Financial Officer
Kyle Jenne Executive
Louis O'Dea Chief Medical Officer

4 Former Executives

You’re viewing 3 of 7 executives. Get the full list »

Akcea Therapeutics Board Members (6)

Name Representing Role Since Contact
Info
000000 00000 000 Self Board Member 000 0000
0000000 0000 Self Board Member 000 0000
00000000 00000 Akcea Therapeutics Board Member 000 0000

3 Former Board Members

You’re viewing 3 of 6 board members. Get the full list »